Pelthos Therapeutics to Participate in Upcoming September Investor Conferences
DURHAM, N.C., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company (“Pelthos” or the...
News
Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled
On Track To Be First Mover In $7Bn Addressable Market With No Current Therapeutic OptionsBy: Benzinga Staff Writer CARDIFF, UK...
Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response...
CorMedix Announces Strategic Minority Investment in Talphera
BERKELEY HEIGHTS, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing...
I-Mab Announces Acceleration of Givastomig Investment and Leadership Appointments
Expands investment in givastomig in 1L metastatic gastric cancers, with plans to initiate a global randomized Phase 2 study in...
Vivos Inc. Demonstrates Precision in Precision Radionuclide Therapy
Kennewick, WA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) announced new data demonstrating the exceptional precision of...
Entera Bio Presents Positive Effects of EB613 on Both Trabecular and Cortical Bone in Postmenopausal Women with Osteoporosis at ASBMR 2025
EB613 Demonstrates Significant Effects on Both Trabecular and Cortical Bone Compartments After Just 6 Months of Treatment in Phase 2...
Microbot Medical® Receives FDA 510(k) Clearance for Its LIBERTY® Endovascular Robotic System
LIBERTY Endovascular Robotic System * Microbot Medical® Receives FDA 510(k) Clearance for Its LIBERTY® Endovascular Robotic System Accelerated Launch Readiness...
Real-world evidence supports clinical effectiveness of the neffy® nasal adrenaline spray
ALK (ALKB:DC / OMX: ALK B) today announced that real-world evidence evaluating the clinical performance of the nasal adrenaline spray...
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Complete the Acquisition of Dura Medical; Initial Acquisition in Network of Interventional Psychiatry Clinics
Dura Medical, together with pending acquisitions of Neurospa TMS and Cohen & Associates, to provide contiguous coverage at more than...
Belite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors
Transaction led by RA Capital Management with participation from Eventide Asset Management, Marshall Wace, RTW Investments, Soleus Capital and Vestal...
Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030
Announces Commitment for New $40 Million Revolving Credit Facility Issues Conditional Notice of Redemption of 11.875% Senior Notes due 2027...
Vaxart Announces Adjournment of Special Meeting of Stockholders
Meeting adjourned to September 19, 2025 at 8:30 a.m. Pacific Time Adjournment provides stockholders with more time given changes in Board composition, additional...
Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025
Data to be presented in the Immunotherapy & Cell Therapy in Sarcoma: Emerging Frontiers session at the Connective Tissue Oncology...
Spectral Medical Sponsors Unite for Sepsis Symposium, Chicago September 8 – 9, 2025
Company to present at session titled “Personalizing Sepsis Treatment” TORONTO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral”...
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRINCETON, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and...
Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer
WALTHAM, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to...
OncoC4 to Present Global Pivotal Phase 3 Trial Design for Next-Generation CTLA-4 Antibody Gotistobart Monotherapy Being Co-Developed with BioNTech in NSCLC at the IASLC 2025 World Conference on Lung Cancer
PRESERVE-003 is evaluating gotistobart vs. docetaxel in patients with squamous non-small cell lung cancer (sqNSCLC) who have progressed on chemotherapy...
Real-World Evidence Supports Clinical Effectiveness of neffy® (epinephrine nasal spray) in Patients Experiencing Anaphylaxis
Findings accepted for publication in the official journal of the American College of Allergy, Asthma and Immunology About 9 out...
Alignment Healthcare Names Matt Eyles Executive Vice President of Government & Business Strategy
Seasoned industry leader to strengthen company’s strategic engagement and policy voice in Medicare AdvantageORANGE, Calif., Sept. 08, 2025 (GLOBE NEWSWIRE)...